Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AIDS, Not PDUFA Pressure, Underlies Post-Market Safety Event Surge – Lutter

Executive Summary

DURHAM, N.C. - Any surge in FDA post-market safety actions stems from the rapid approval of AIDS drugs during the 1990s, and not errors made as a result of review time constraints created by user fee deadlines, Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter maintained June 23
Advertisement

Related Content

Have PDUFA Dates Increased Safety Issues? Study Says Yes, FDA Says No
Have PDUFA Dates Increased Safety Issues? Study Says Yes, FDA Says No
Advertisement
UsernamePublicRestriction

Register

PS049826

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel